PAS
LGND icon

Park Avenue Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Park Avenue Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Buy
+1,276
New +$301K ﹤0.01% 1391
2026
Q1 		– Sell
-1,402
Closed -$265K – 1625
2025
Q4 		$265K Buy
+1,402
New +$269K ﹤0.01% 1361

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Park Avenue Securities's LGND Position: Q2 2026 in Review

Park Avenue Securities opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,276 shares worth $403K. The stake represents ﹤0.01% of the portfolio and ranks #1391 among its holdings. This is a return to the name: Park Avenue Securities previously reported a position in LGND as recently as Q4 2025.

Park Avenue Securities first reported a position in LGND in Q4 2025 and has held it in 2 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Park Avenue Securities held 1,276 shares of Ligand Pharmaceuticals worth $403K as of Q2 2026.
  • Ligand Pharmaceuticals was a new Park Avenue Securities position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Park Avenue Securities's portfolio in Q2 2026, its #1391 holding.
  • Park Avenue Securities first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.